APRE — Aprea Therapeutics, Inc. Dilution Risk Tracker

Aprea Therapeutics, Inc. (APRE) has a DilutionScore of 51/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

DilutionWatch's EDGAR monitoring for APRE shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for APRE in real-time, scanning EDGAR every 60 seconds. A recent S-3 or registration statement filing appears in APRE's filing history — this warrants monitoring for subsequent prospectus supplements (Form 424B), which indicate active capital raising. The DilutionWatch screener shows real-time score changes for APRE alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.